Invivo Capital, through its Invivo Ventures fund, has invested in OneChain Immunotherapeutics, a spin-off founded by the Josep Carreras Leukaemia Research Institute, Catalan Institution for Research and Advanced Studies (ICREA) and Dr Pablo Menéndez last June in Barcelona.

OneChain Immunotherapeutics raised €3.05 million in seed capital through this round which also included the Spanish Ministry of Science and Innovation, through its Innvierte programme managed by the CDTI, and the Josep Carreras Foundation in a clear commitment to bringing to its patients the research carried out by Dr Pablo Menéndez’s group. Dr Pablo Menéndez is an ICREA research professor, research director of the Josep Carreras Leukaemia Research Institute Campus Clinic-UB and a global benchmark in childhood leukaemia.

This July, Invivo Capital also led the €4.1-million investment in Telum Therapeutics (Pamplona, Spain) to advance development of new therapies based on synthetic biology to treat infectious diseases caused by multi-resistant bacteria, and participated in the €4.25-million investment in Arthex Biotech (Valencia, Spain) to develop a therapy for myotonic dystrophy.

Photo: from left to right, in front, Evarist Feliu (Josep Carreras Foundation), Lluís Pareras (Invivo), Pablo Menéndez (OneChain); standing, Emilià Pola (ICREA) and Albert Ferrer (Invivo).